FDA grants breakthrough therapy status to MSK ’s Burtomab neuroblastoma therapy

Memorial Sloan Kettering Cancer Center (MSK)-developed Burtomab has received breakthrough therapy designation from the US Food and Drug Administration (FDA) for the treatment of pediatric patients with relapsed or refractory neuroblastoma with centra …
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news